Engineered TB bacteria could offer new hope for bladder cancer patients

NCT ID NCT06800963

Recruiting now Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new version of the BCG therapy, made from a genetically modified bacterium, for people with non-muscle invasive bladder cancer (NMIBC) who have not received BCG before. The treatment is given directly into the bladder through a catheter. The study aims to check if the therapy is safe and to get an early look at how well it works. About 40 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Recombinant Mycobacterium (rMBCG), a genetically modified version of the BCG vaccine, given directly into the bladder via a catheter.
What this could lead to: If successful, this could offer a more targeted and potentially safer treatment option for people with early-stage bladder cancer, reducing the need for bladder removal surgery.
What could go wrong: This is an early phase 1/2 trial with only 40 participants, so results are preliminary. The new therapy may cause side effects similar to standard BCG, such as bladder irritation or infection, and may not prove more effective than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA IN SITU OF BLADDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder carcinoma in situ bladder papillary urothelial neoplasm non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms superficial urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NMIBC

Contacts and locations

Locations

Arizona Clinical Trials
NOT_YET_RECRUITING

Chandler, Arizona, 85224, United States
Conrad Pearson Clinic
NOT_YET_RECRUITING

Germantown, Tennessee, 38138, United States
Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
Golden State Urology
RECRUITING

Sacramento, California, 95823, United States
Michigan Institute of Urology & Solaris Health
RECRUITING

Troy, Michigan, 48084, United States
MidLantic Urology
RECRUITING

Cynwyd, Pennsylvania, 19004, United States
Potamac Urology Center
NOT_YET_RECRUITING

Alexandria, Virginia, 22311, United States
SUNY Upstate Medical University
NOT_YET_RECRUITING

Syracuse, New York, 13210, United States
Urology Associates, P.C.
RECRUITING

Nashville, Tennessee, 37209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.